Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can
induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic
spectrum.
The investigators will also examine possible associations between GLP-1 treatment and
peripheral metabolic parameters such as change in body fat and HbA1c. Moreover, the GLP-1
analogue treatment will be associated with the effects/changes on cognition and subjective
quality of life. Possible cerebral effects (pro-cognitive) of the GLP-1 analogue treatment
will associated and correlated with changes in the brain, functional magnetic resonance
imaging (fMRI).